ArticleBJU international2025
Robot-assisted partial nephrectomy using the Hugo™ RAS System: first multicentre study and Tetrafecta achievement.
Article in BJU international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Modified internal traction technique for improved exposure in retroperitoneal robot-assisted partial nephrectomy for dorsal hilar tumors: a preliminary single-center experience.Journal of robotic surgery · 2026Article
- Alternative set up strategies for upper tract robotic surgery with the Hugo RAS - experience from an early adopter institution.Journal of robotic surgery · 2026Article
- Exploratory activity-based direct cost analysis of robotic platforms in urologic surgery.Journal of robotic surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the perioperative outcomes and the rate of Tetrafecta achievement in robot-assisted partial nephrectomy (RAPN) cases performed using the Hugo™ robot-assisted surgery (RAS) system (Medtronic, Minneapolis, MN, USA). PATIENTS AND
methodsData from five tertiary care referral centres performing RAPN with the Hugo RAS System since October 2022 were collected. For the study purpose, a novel Tetrafecta was defined as a proxy for surgical quality. This included the coexistence of negative surgical margins, absence of intraoperative and Clavien-Dindo Grade ≥II postoperative complications, and 90-day decline in estimated glomerular filtration rate of no more than 30% from baseline.
resultsA total of 140 patients, who underwent RAPN with the Hugo RAS system, were included. The median (interquartile range [IQR]) docking, console, and total operative times were 5 (4-7) min, 79 (45.5-135) min, and 150 (96-205) min, respectively. The median (IQR) estimated blood loss was 150 (100-300) mL. No additional port placements were required, and no conversions to open surgery occurred. Overall, postoperative complications were observed in 20.7% of cases, 5% of which were classified as major (Clavien-Dindo Grade >II). Tetrafecta was achieved in 80% of cases. Multivariate logistic regression analysis showed that R.E.N.A.L. (Radius, Exophytic/Endophytic, Nearness to collecting system or sinus, Anterior/Posterior, Location) nephrometry score (odds ratio [OR] 0.69; P = 0.01) and Hugo RAS surgical experience (OR 1.03; P = 0.02) were independent predictors of Tetrafecta achievement.
conclusionsRelying on the largest multicentre series, our findings demonstrate that this novel robotic platform enables safe and effective RAPN, achieving a satisfactory Tetrafecta rate. These results would support the adoption of the Hugo RAS system to perform RAPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.